PriceTargets.com logo

Arcturus Therapeutics - ARCT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 427.09%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$6.83 As of 12/4/2025 05:00 PM ET
▲ +0.24 (3.64%)

This chart shows the closing price for ARCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcturus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARCT

Analyst Price Target is $36.00
▲ +427.09% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $72.00 and a low forecast of $9.00. The average price target represents a 427.09% upside from the last price of $6.83.

This chart shows the closing price for ARCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Arcturus Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2025CitigroupLower TargetNeutral ➝ Neutral$12.00 ➝ $9.00
11/11/2025Piper SandlerLower TargetOverweight ➝ Overweight$140.00 ➝ $72.00
11/11/2025HC WainwrightLower TargetNeutral ➝ Neutral$12.00 ➝ $9.00
10/24/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/24/2025HC WainwrightReiterated RatingBuy ➝ Neutral$60.00 ➝ $12.00
10/23/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$42.00 ➝ $20.00
10/23/2025CitigroupDowngradeBuy ➝ Neutral$49.00 ➝ $12.00
10/22/2025BTIG ResearchLower TargetBuy ➝ Buy$48.00 ➝ $23.00
10/22/2025GuggenheimDowngradeBuy ➝ Neutral
10/13/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/10/2025CitigroupReiterated RatingBuy ➝ Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/4/2025HC WainwrightInitiated CoverageBuy ➝ Buy$60.00
8/22/2025Leerink PartnersLower TargetOutperform ➝ Outperform$63.00 ➝ $54.00
8/12/2025CitigroupReiterated RatingBuy ➝ Buy$47.00 ➝ $49.00
8/12/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$45.00 ➝ $42.00
7/2/2025ScotiabankReiterated RatingOutperform ➝ Outperform
7/2/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
5/28/2025ScotiabankInitiated CoverageSector Outperform$32.00
5/14/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025CitigroupReiterated RatingBuy ➝ Buy
5/13/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$68.00 ➝ $66.00
4/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
3/10/2025BTIG ResearchSet TargetBuy ➝ Buy$48.00
3/10/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$74.00 ➝ $68.00
3/7/2025HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $60.00
3/7/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
3/7/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$58.00 ➝ $50.00
2/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
1/28/2025BTIG ResearchInitiated CoverageBuy$41.00
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
1/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
12/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
12/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/12/2024Leerink PartnrsUpgradeStrong-Buy
8/12/2024Leerink PartnersInitiated CoverageOutperform$70.00
8/8/2024HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $63.00
8/6/2024Cantor FitzgeraldReiterated RatingOverweight
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/23/2024William BlairReiterated RatingOutperform
5/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$87.00 ➝ $86.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
3/8/2024William BlairReiterated RatingOutperform
2/8/2024CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $48.00
12/13/2023Canaccord Genuity GroupInitiated CoverageBuy
12/13/2023Canaccord Genuity GroupInitiated CoverageBuy$90.00
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
11/15/2023William BlairReiterated RatingOutperform
11/6/2023William BlairReiterated RatingOutperform
9/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
9/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
7/24/2023William BlairInitiated CoverageOutperform$71.00
7/17/2023Wells Fargo & CompanyBoost Target$35.00 ➝ $45.00
7/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
7/14/2023GuggenheimReiterated RatingBuy
7/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
5/11/2023HC WainwrightUpgradeNeutral ➝ Buy$19.00 ➝ $51.00
3/29/2023HC WainwrightReiterated RatingNeutral$19.00
3/29/2023GuggenheimReiterated RatingBuy$36.00
11/14/2022Wells Fargo & CompanyInitiated CoverageOverweight$35.00
11/10/2022The Goldman Sachs GroupBoost TargetSell$8.00 ➝ $14.00
11/10/2022Robert W. BairdDowngradeNeutral ➝ Underperform$18.00
11/3/2022CitigroupUpgradeNeutral ➝ Buy$22.00 ➝ $35.00
11/2/2022BarclaysUpgradeUnderweight ➝ Equal Weight$16.00 ➝ $25.00
11/2/2022Cantor FitzgeraldBoost TargetOverweight$39.00 ➝ $44.00
8/10/2022Brookline Capital ManagementReiterated RatingBuy
8/10/2022Wells Fargo & CompanyLower TargetOverweight$105.00 ➝ $98.00
8/10/2022BarclaysLower TargetUnderweight$17.00 ➝ $16.00
8/10/2022Raymond James FinancialDowngradeMarket Perform ➝ Underperform
5/24/2022The Goldman Sachs GroupLower TargetSell$14.00 ➝ $8.00
5/11/2022GuggenheimLower Target$83.00 ➝ $36.00
5/11/2022Robert W. BairdUpgradeUnderperform ➝ Neutral$21.00 ➝ $18.00
5/10/2022BarclaysLower Target$21.00 ➝ $17.00
5/10/2022HC WainwrightLower Target$25.00 ➝ $19.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
4/21/2022CitigroupDowngradeBuy ➝ Neutral$86.00 ➝ $29.00
3/25/2022Wells Fargo & CompanyLower TargetOverweight$107.00 ➝ $105.00
3/15/2022CitigroupLower TargetBuy$114.00 ➝ $86.00
3/1/2022HC WainwrightLower Target$47.00 ➝ $25.00
3/1/2022Wells Fargo & CompanyLower TargetOverweight$118.00 ➝ $107.00
3/1/2022Cantor FitzgeraldLower Target$93.00 ➝ $86.00
3/1/2022BarclaysLower Target$31.00 ➝ $21.00
1/31/2022Raymond James FinancialUpgradeUnderperform ➝ Market Perform
1/26/2022HC WainwrightLower Target$47.00 ➝ $33.00
11/16/2021Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $93.00
11/9/2021BarclaysLower TargetPositive ➝ Underweight$46.00 ➝ $31.00
8/25/2021CitigroupLower TargetBuy$118.00 ➝ $114.00
8/12/2021Raymond James FinancialDowngradeMarket Perform ➝ Underperform
8/10/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$29.00
8/10/2021Cantor FitzgeraldBoost TargetOverweight$71.00 ➝ $85.00
8/10/2021Robert W. BairdDowngradeNeutral ➝ Underperform$31.00
7/2/2021Cantor FitzgeraldInitiated CoverageOverweight$71.00
6/24/2021The Goldman Sachs GroupInitiated CoverageNeutral$29.00 ➝ $34.00
6/21/2021BarclaysDowngradeEqual Weight ➝ Underweight$33.00 ➝ $25.00
5/12/2021B. RileyReiterated RatingSell$35.00 ➝ $23.00
5/11/2021BarclaysLower TargetEqual Weight$46.00 ➝ $33.00
3/8/2021B. RileyLower TargetPositive ➝ Sell$45.00 ➝ $35.00
3/2/2021Roth CapitalLower TargetSell$77.00 ➝ $45.00
2/17/2021B. RileyDowngradeNeutral ➝ Sell
1/15/2021B. RileyDowngradeBuy ➝ Neutral$138.00 ➝ $77.00
1/7/2021Wells Fargo & CompanyInitiated CoverageOverweight$118.00
12/29/2020HC WainwrightDowngradeBuy ➝ Neutral$84.00 ➝ $50.00
12/29/2020Robert W. BairdDowngradeOutperform ➝ Neutral$79.00 ➝ $69.00
12/29/2020BarclaysDowngradeOverweight ➝ Equal Weight$68.00 ➝ $46.00
12/29/2020Raymond James FinancialDowngradeOutperform ➝ Market Perform$46.00
12/23/2020Roth CapitalDowngradeBuy ➝ Sell$77.00
12/14/2020Smith Barney CitigroupBoost Target$62.00 ➝ $133.00
12/7/2020B. RileyBoost TargetBuy$64.00 ➝ $111.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 9 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 5 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Arcturus Therapeutics logo
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $6.83
Low: $6.47
High: $6.85

50 Day Range

MA: $12.70
Low: $5.90
High: $23.16

52 Week Range

Now: $6.83
Low: $5.85
High: $24.17

Volume

666,188 shs

Average Volume

895,528 shs

Market Capitalization

$194.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?

The following Wall Street research analysts have issued research reports on Arcturus Therapeutics in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Leerink Partners, Piper Sandler, Scotiabank, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for ARCT.

What is the current price target for Arcturus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Arcturus Therapeutics in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 427.1%. Piper Sandler has the highest price target set, predicting ARCT will reach $72.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for Arcturus Therapeutics in the next year.
View the latest price targets for ARCT.

What is the current consensus analyst rating for Arcturus Therapeutics?

Arcturus Therapeutics currently has 1 sell rating, 4 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARCT.

What other companies compete with Arcturus Therapeutics?

Other companies that are similar to Arcturus Therapeutics include CorMedix, Aquestive Therapeutics, BGM Group, Gyre Therapeutics and CytomX Therapeutics. Learn More about companies similar to Arcturus Therapeutics.

How do I contact Arcturus Therapeutics' investor relations team?

Arcturus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 900-2660 and its investor relations email address is [email protected]. The official website for Arcturus Therapeutics is www.arcturusrx.com. Learn More about contacing Arcturus Therapeutics investor relations.